patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_500550 | REC_0003401 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 15.5 | 75 | female | 1 | 14 | 7.3 | 0 | alectinib 600 mg BID | 59.9 | true | MSI-H | 2026-03-15T05:35:57.685151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470897 | REC_0003402 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 12.6 | 75 | female | 1 | 20 | 4.1 | 9 | entrectinib 600 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:57.685386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116926 | REC_0003403 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 14.3 | 82 | female | 1 | 12 | 3.6 | 5 | pembrolizumab 200 mg q3w | 7.8 | false | MSI-H | 2026-03-15T05:35:57.685622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124073 | REC_0003404 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 5.8 | 67 | female | 1 | 13 | 5.7 | 2 | pembrolizumab 200 mg q3w | 18.8 | true | MSS | 2026-03-15T05:35:57.685852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566633 | REC_0003405 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 8.5 | 62 | female | 0 | 20 | 4.7 | 1 | pembrolizumab 200 mg q3w | 22.6 | false | MSS | 2026-03-15T05:35:57.686088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486879 | REC_0003406 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 4.3 | 69 | female | 1 | 13 | 7.1 | 1 | alectinib 600 mg BID | 15.7 | true | MSS | 2026-03-15T05:35:57.686317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830520 | REC_0003407 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 3.9 | 84 | female | 2 | 50 | 6 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:35:57.686607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813826 | REC_0003408 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 15.3 | 68 | female | 1 | 20 | 6.3 | 1 | osimertinib 80 mg daily | 22.1 | false | MSS | 2026-03-15T05:35:57.686848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285321 | REC_0003409 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 8.7 | 64 | female | 0 | 15 | 3.3 | 5 | pembrolizumab 200 mg q3w | 11.5 | false | MSS | 2026-03-15T05:35:57.687081+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546165 | REC_0003410 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.9 | 68 | female | 0 | 13 | 6 | 6 | osimertinib 80 mg daily | 6.2 | true | MSS | 2026-03-15T05:35:57.687311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835612 | REC_0003411 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10 | 63 | female | 1 | 19 | 6.9 | 2 | sotorasib 960 mg daily | 21.9 | false | MSS | 2026-03-15T05:35:57.687543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536060 | REC_0003412 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 18 | 80 | female | 1 | 13 | 5.6 | 8 | entrectinib 600 mg daily | 4.5 | true | MSS | 2026-03-15T05:35:57.687772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797310 | REC_0003413 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 27 | 3.4 | 62 | female | 1 | 48 | 5.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 15.4 | false | MSS | 2026-03-15T05:35:57.688003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805275 | REC_0003414 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 20 | 9.9 | 65 | male | 0 | 16 | 5.8 | 0 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:57.688370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795272 | REC_0003415 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 9.6 | 72 | female | 1 | 18 | 5.1 | 2 | osimertinib 80 mg daily | 21.8 | true | MSS | 2026-03-15T05:35:57.688619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850461 | REC_0003416 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 10.6 | 73 | female | 2 | 15 | 5.6 | 1 | sotorasib 960 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:57.688858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614494 | REC_0003417 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 11.8 | 67 | female | 1 | 13 | 5.3 | 2 | sotorasib 960 mg daily | 22.1 | false | MSI-H | 2026-03-15T05:35:57.689097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837544 | REC_0003418 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 21.7 | 80 | female | 3 | 19 | 4.2 | 2 | osimertinib 80 mg daily | 22.5 | true | MSI-H | 2026-03-15T05:35:57.689330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560570 | REC_0003419 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.8 | 71 | female | 1 | 61 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.8 | false | MSS | 2026-03-15T05:35:57.689559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288428 | REC_0003420 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 35 | 6.4 | 66 | female | 0 | 15 | 6.7 | 8 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.689848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536984 | REC_0003421 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 6.3 | 79 | male | 2 | 55 | 6 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:35:57.690083+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324097 | REC_0003422 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 8 | 64 | female | 1 | 64 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 28.9 | false | MSS | 2026-03-15T05:35:57.690316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525292 | REC_0003423 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 12.5 | 77 | female | 1 | 19 | 6.2 | 2 | osimertinib 80 mg daily | 7 | false | MSI-H | 2026-03-15T05:35:57.690550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766433 | REC_0003424 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 15.7 | 78 | female | 1 | 18 | 6 | 6 | alectinib 600 mg BID | 7.6 | true | MSS | 2026-03-15T05:35:57.690780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818231 | REC_0003425 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 3.8 | 58 | male | 0 | 66 | 6.6 | 7 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:57.691012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771189 | REC_0003426 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.6 | 53 | male | 0 | 45 | 6.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 17.1 | true | MSS | 2026-03-15T05:35:57.691247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309993 | REC_0003427 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 3.6 | 63 | male | 0 | 17 | 4.4 | 4 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:57.691478+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512789 | REC_0003428 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 17.3 | 60 | female | 1 | 13 | 5.4 | 3 | osimertinib 80 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:35:57.691714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755711 | REC_0003429 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 14 | 4.3 | 50 | male | 0 | 9 | 5.3 | 6 | osimertinib 80 mg daily | 5.6 | false | MSS | 2026-03-15T05:35:57.691946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357597 | REC_0003430 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 9.7 | 59 | male | 0 | 14 | 4.6 | 1 | osimertinib 80 mg daily | 20.3 | true | MSS | 2026-03-15T05:35:57.692257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557668 | REC_0003431 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 16.6 | 69 | female | 1 | 23 | 3.5 | 7 | entrectinib 600 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:57.692503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526038 | REC_0003432 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 15.3 | 59 | female | 0 | 15 | 6.1 | 6 | entrectinib 600 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:57.692743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466713 | REC_0003433 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10.1 | 75 | male | 2 | 25 | 6.4 | 6 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:35:57.693037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644240 | REC_0003434 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 3.2 | 73 | female | 0 | 13 | 5.6 | 6 | pembrolizumab 200 mg q3w | 5.3 | true | MSS | 2026-03-15T05:35:57.693275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116978 | REC_0003435 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.6 | 68 | female | 1 | 20 | 4 | 4 | alectinib 600 mg BID | 19 | false | MSI-H | 2026-03-15T05:35:57.693519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687386 | REC_0003436 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 16 | 3 | 70 | female | 3 | 47 | 6.5 | 2 | pembrolizumab 200 mg q3w | 18.6 | false | MSS | 2026-03-15T05:35:57.693752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745161 | REC_0003437 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 12 | 75 | female | 1 | 10 | 6.9 | 0 | sotorasib 960 mg daily | 60.6 | false | MSS | 2026-03-15T05:35:57.693987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505215 | REC_0003438 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 11.7 | 67 | female | 1 | 13 | 4.9 | 0 | sotorasib 960 mg daily | 29.6 | true | MSI-H | 2026-03-15T05:35:57.694223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528768 | REC_0003439 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 8.6 | 68 | male | 0 | 18 | 4.8 | 5 | alectinib 600 mg BID | 15.2 | false | MSS | 2026-03-15T05:35:57.694461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592863 | REC_0003440 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.7 | 53 | male | 0 | 67 | 5.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.3 | true | MSS | 2026-03-15T05:35:57.694691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611812 | REC_0003441 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 13.4 | 67 | female | 0 | 17 | 6.9 | 4 | alectinib 600 mg BID | 9.8 | false | MSI-H | 2026-03-15T05:35:57.694929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177596 | REC_0003442 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 11.8 | 66 | female | 0 | 15 | 5.7 | 1 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:35:57.695162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389657 | REC_0003443 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 10.4 | 72 | male | 2 | 15 | 6.6 | 1 | sotorasib 960 mg daily | 20.9 | true | MSS | 2026-03-15T05:35:57.695398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148696 | REC_0003444 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.7 | 64 | male | 1 | 31 | 3.8 | 3 | entrectinib 600 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:57.695629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771100 | REC_0003445 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 14.4 | 71 | male | 1 | 25 | 5.6 | 1 | alectinib 600 mg BID | 18 | true | MSI-H | 2026-03-15T05:35:57.695866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306048 | REC_0003446 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 7.2 | 54 | female | 0 | 15 | 4.8 | 5 | osimertinib 80 mg daily | 4.6 | true | MSS | 2026-03-15T05:35:57.696244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882289 | REC_0003447 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.1 | 62 | female | 1 | 1 | 4.5 | 7 | entrectinib 600 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.696489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872388 | REC_0003448 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 23 | 7.4 | 61 | male | 0 | 39 | 6.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 49.6 | false | MSS | 2026-03-15T05:35:57.696727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129064 | REC_0003449 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 11.1 | 71 | female | 1 | 20 | 5.2 | 4 | osimertinib 80 mg daily | 8.6 | true | MSI-H | 2026-03-15T05:35:57.696962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591160 | REC_0003450 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 8.9 | 72 | male | 1 | 10 | 6.3 | 2 | pembrolizumab 200 mg q3w | 16 | false | MSS | 2026-03-15T05:35:57.697199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309485 | REC_0003451 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.9 | 88 | female | 2 | 22 | 6.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.7 | false | MSS | 2026-03-15T05:35:57.697432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351627 | REC_0003452 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.4 | 40 | male | 0 | 22 | 5.4 | 7 | pembrolizumab 200 mg q3w | 13.5 | true | MSS | 2026-03-15T05:35:57.697662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333429 | REC_0003453 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 23 | 13.7 | 67 | female | 1 | 24 | 4.2 | 0 | alectinib 600 mg BID | 56.5 | false | MSS | 2026-03-15T05:35:57.697895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610082 | REC_0003454 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 4.1 | 69 | female | 0 | 56 | 6.4 | 0 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:35:57.698122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782117 | REC_0003455 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 19.9 | 71 | male | 2 | 17 | 4.7 | 3 | sotorasib 960 mg daily | 12.1 | false | MSI-H | 2026-03-15T05:35:57.698361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749050 | REC_0003456 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 9.6 | 89 | female | 3 | 3 | 4.8 | 2 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:57.698588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513176 | REC_0003457 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.1 | 65 | female | 0 | 30 | 3.5 | 5 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:57.698823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593976 | REC_0003458 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 14.4 | 68 | female | 1 | 18 | 7.2 | 3 | osimertinib 80 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:57.699052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362455 | REC_0003459 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 9.2 | 69 | female | 0 | 67 | 3.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.8 | true | MSS | 2026-03-15T05:35:57.699336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913623 | REC_0003460 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 14.3 | 61 | female | 0 | 17 | 5.5 | 2 | alectinib 600 mg BID | 26.2 | false | MSI-H | 2026-03-15T05:35:57.699590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500770 | REC_0003461 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 6.2 | 68 | male | 1 | 5 | 4.8 | 7 | pembrolizumab 200 mg q3w | 11.1 | true | MSS | 2026-03-15T05:35:57.699828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417957 | REC_0003462 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 7.8 | 62 | female | 1 | 15 | 6.2 | 7 | sotorasib 960 mg daily | 22.4 | false | MSS | 2026-03-15T05:35:57.700065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468648 | REC_0003463 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 34 | 12.9 | 69 | female | 0 | 11 | 5.4 | 1 | entrectinib 600 mg daily | 18.3 | true | MSS | 2026-03-15T05:35:57.700378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226572 | REC_0003464 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 10.6 | 76 | female | 1 | 8 | 4.5 | 4 | entrectinib 600 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:57.700645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902703 | REC_0003465 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 15.2 | 56 | female | 1 | 15 | 6 | 3 | osimertinib 80 mg daily | 6.8 | false | MSI-H | 2026-03-15T05:35:57.700896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585229 | REC_0003466 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 8.3 | 88 | male | 1 | 59 | 4.5 | 1 | pembrolizumab 200 mg q3w | 22.3 | true | MSS | 2026-03-15T05:35:57.701135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867308 | REC_0003467 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 16 | 68 | male | 1 | 19 | 5.8 | 2 | sotorasib 960 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:57.701383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518203 | REC_0003468 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.7 | 62 | male | 1 | 39 | 4.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.5 | false | MSS | 2026-03-15T05:35:57.701633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689294 | REC_0003469 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 8.7 | 67 | male | 1 | 29 | 7.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.7 | true | MSS | 2026-03-15T05:35:57.701885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345682 | REC_0003470 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.1 | 72 | female | 2 | 44 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 28.5 | true | MSS | 2026-03-15T05:35:57.702134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596360 | REC_0003471 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 11.8 | 65 | female | 1 | 15 | 4.5 | 4 | sotorasib 960 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:57.702386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811934 | REC_0003472 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 11.2 | 61 | male | 0 | 13 | 3.5 | 7 | osimertinib 80 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:57.702759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369022 | REC_0003473 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 16 | 63 | male | 1 | 15 | 4 | 1 | osimertinib 80 mg daily | 24.8 | true | MSS | 2026-03-15T05:35:57.703006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546564 | REC_0003474 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 18.4 | 66 | female | 0 | 9 | 4.7 | 6 | pembrolizumab 200 mg q3w | 5.6 | true | MSI-H | 2026-03-15T05:35:57.703251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872862 | REC_0003475 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 7.6 | 80 | female | 1 | 8 | 6.7 | 1 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:35:57.703485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792268 | REC_0003476 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 9.5 | 61 | female | 1 | 15 | 4.9 | 6 | entrectinib 600 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:57.703720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174630 | REC_0003477 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 14.5 | 69 | female | 1 | 7 | 5.5 | 2 | sotorasib 960 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:57.703961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930586 | REC_0003478 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.1 | 57 | male | 1 | 23 | 7.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.8 | false | MSS | 2026-03-15T05:35:57.704277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443301 | REC_0003479 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 12.1 | 77 | female | 2 | 14 | 6.4 | 6 | sotorasib 960 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:57.704544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378998 | REC_0003480 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 5.6 | 63 | female | 0 | 49 | 6.1 | 2 | pembrolizumab 200 mg q3w | 12.8 | true | MSS | 2026-03-15T05:35:57.704813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238235 | REC_0003481 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 34 | 7.6 | 59 | female | 1 | 21 | 4.9 | 7 | pembrolizumab 200 mg q3w | 11.3 | false | MSS | 2026-03-15T05:35:57.705075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394089 | REC_0003482 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 6.6 | 57 | male | 1 | 16 | 5.6 | 2 | alectinib 600 mg BID | 19 | true | MSS | 2026-03-15T05:35:57.705334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583883 | REC_0003483 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.9 | 65 | male | 1 | 34 | 6.2 | 5 | pembrolizumab 200 mg q3w | 8.1 | true | MSS | 2026-03-15T05:35:57.705595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208964 | REC_0003484 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 22 | 10.8 | 90 | female | 2 | 14 | 7.9 | 0 | sotorasib 960 mg daily | 53.6 | false | MSS | 2026-03-15T05:35:57.705862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784716 | REC_0003485 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 17.7 | 81 | male | 0 | 17 | 6.2 | 7 | osimertinib 80 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:57.706261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966249 | REC_0003486 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 9.3 | 60 | male | 1 | 13 | 3.9 | 1 | sotorasib 960 mg daily | 19.1 | true | MSS | 2026-03-15T05:35:57.706515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970752 | REC_0003487 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.2 | 67 | male | 0 | 20 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:57.706763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342598 | REC_0003488 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 9 | 62 | female | 1 | 10 | 6.3 | 7 | entrectinib 600 mg daily | 17.2 | true | MSS | 2026-03-15T05:35:57.706997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919079 | REC_0003489 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 8.5 | 76 | female | 0 | 10 | 7 | 7 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:35:57.707228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280912 | REC_0003490 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.8 | 70 | male | 1 | 31 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:57.707463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906802 | REC_0003491 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 9.6 | 66 | female | 1 | 10 | 5.6 | 1 | alectinib 600 mg BID | 26.2 | true | MSS | 2026-03-15T05:35:57.707692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471366 | REC_0003492 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.4 | 56 | male | 1 | 55 | 5.6 | 8 | carboplatin + paclitaxel + pembrolizumab | 15.4 | false | MSS | 2026-03-15T05:35:57.707924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648533 | REC_0003493 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.5 | 65 | male | 0 | 7 | 5.6 | 4 | entrectinib 600 mg daily | 7.1 | true | MSS | 2026-03-15T05:35:57.708219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529815 | REC_0003494 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12.1 | 60 | female | 1 | 13 | 6.2 | 5 | osimertinib 80 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:35:57.708462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480015 | REC_0003495 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 15.4 | 74 | female | 1 | 7 | 4 | 3 | sotorasib 960 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:57.708701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995157 | REC_0003496 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.8 | 64 | male | 1 | 8 | 5.3 | 5 | entrectinib 600 mg daily | 6.1 | true | MSS | 2026-03-15T05:35:57.708936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697554 | REC_0003497 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 3.8 | 55 | female | 1 | 18 | 6 | 2 | pembrolizumab 200 mg q3w | 10.1 | true | MSS | 2026-03-15T05:35:57.709168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442544 | REC_0003498 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 34 | 10.8 | 71 | female | 2 | 17 | 5.8 | 1 | osimertinib 80 mg daily | 24.2 | false | MSS | 2026-03-15T05:35:57.709470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823396 | REC_0003499 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 16.4 | 65 | female | 0 | 15 | 5 | 6 | osimertinib 80 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:35:57.709711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677210 | REC_0003500 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 10.9 | 58 | female | 1 | 15 | 5.3 | 3 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:57.709945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.